您当前的位置: 首页 > 资源详情

CIDRAP,10月11日,Merck applies for approval of first COVID-19 antiviral pill

编译者:YUTING发布时间:2021-10-15点击量:63 来源栏目:最新研究

Today, pharmaceutical giant Merck submitted an emergency use authorization (EUA) application to the Food and Drug Administration (FDA) for molnupiravir, its oral antiviral medication, for the treatment of mild to moderate COVID-19 in adults at risk for severe disease.

This category includes patients over 60 years and those diagnosed as having obesity, diabetes, or heart disease.

The drug, named after Thor's hammer in Norse mythology, would be the first pill authorized by the FDA to treat COVID-19. Other antivirals used to fight COVID-19 have to be injected or administered intravenously. Merck has previously said that, if approved, the company is ready to supply the US government with 1.7 million doses of the antiviral.

The submission is based on positive results from a phase 3 trial of the drug, which showed that molnupiravir reduced the risk of hospitalization or death by approximately 50%.

"The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data," said Robert M. Davis, Merck chief executive officer and president, in a company press release.

The suggested use of molnupiravir would be four capsules twice a day for 5 days.

COVID-19 cases continue to drop

According to the New York Times tracker, the country recorded 96,549 COVID-19 cases yesterday and 2,000 deaths. The newspaper said cases are dropping most significantly in Southern states that saw the biggest activity during the nation’s fourth wave this summer, which was fueled by the Delta (B1617.2) variant.

Florida, for example, is averaging fewer than 4,000 new cases a day, down from more than 20,000 a day at the end of August.

Northern and western states, including Alaska, Montana, North Dakota, Wyoming, and Minnesota, lead the nation in recent cases per capita; Minnesota's daily case counts increased 36% in the last 2 weeks.

The 7-day average of new daily COVID-19 cases is 95,926, with 1,778 daily deaths, according to the Washington Post tracker. New daily cases fell 10.1% in the past week, deaths fell 6.8%, and hospitalizations fell 8.2%.

提供服务:导出本资源
  1. 1 Nature,11月10日,Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
  2. 2 11月10日_研究人员分析宿主基因对COVID-19严重程度和易感性的影响
  3. 3 11月11日_新冠药物Remestemcel-L二期临床的中期分析结果积极
  4. 4 11月11日_CDC呼吁制定通用口罩规定以减少新冠传播
  5. 5 SSRN,2月20日,Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study
  6. 6 SSRN,2月20日,Mental Health Problems and Social Media Exposure During COVID-19 Outbreak
  7. 7 SSRN,2月20日,Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources
  8. 8 SSRN,2月20日,Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China
  9. 9 Nature,11月10日,Mobility network models of COVID-19 explain inequities and inform reopening
  10. 10 1月27日_Nature报道中国新型冠状病毒最新研究进展:病毒传播速度有多快?
  1. 1 Phys.org,2月21日,Why natural killer cells react to COVID-19
  2. 2 ScienceDaily,2月18日,T-cell responses may help predict protection against SARS-CoV-2 infection in individuals with and without cancer
  3. 3 2月18日_研究发现伊维菌素对轻度至中度COVID-19无效
  4. 4 2月17日_抗磷脂自身抗体可使COVID-19患者出现血栓
  5. 5 2月21日_科学家合成SARS-CoV-2病毒颗粒并发现刺突蛋白的转换机制
  6. 6 2月16日_免疫细胞靶向的SARS-CoV-2蛋白会引发蝙蝠冠状病毒的反应
  7. 7 Sciencedaily,2月17日,Study strengthens case that vitamins cannot treat COVID-19
  8. 8 Medicalxpress,2月16日,Study suggests increased risk of mental health disorders after COVID-19 infection
  9. 9 2月17日_高水平雌激素和抗酸剂可降低COVID-19风险
  10. 10 2月17日_研究发现COVID-19疫苗可提供持久的保护以预防再感染

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190